Compare Figs Inc (FIGS) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figs Inc vs Medpace Holdings Inc — how do they compare? Figs Inc trades at $15.76 (market cap $2.49B), while Medpace Holdings Inc trades at $611.57 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 6.8× Figs Inc's market cap, and Medpace Holdings Inc is more actively traded (223,093 versus 5,964,311). Which is the better fit depends on your goals — on Pluang, investors hold Figs Inc for 33 Days and Medpace Holdings Inc for 14 Days on average.
| FIGS | MEDP | |
|---|---|---|
Market Cap | $2.49B | $16.82B |
Volume | 5,964,311 | 223,093 |
Sector | Consumer Cyclical | Health |
52-Week High | $17.12 | $630.19 |
52-Week Low | $6.90 | $393.42 |
Typical Hold Time | 33 Days | 14 Days |
Enterprise Value | $2.25B | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIGS stock trades at $15.78, up 12.23% with strong technical momentum and bullish moving averages. The company shows accelerating revenue growth from $556M in 2024 to $631M in 2025, with net income improving to $34M. Recent Q2 2026 earnings beat expectations by 64%, and international sales surged 67% according to Zacks Research on August 20, 2026. The stock faces valuation concerns with a P/E of 45.39, but analyst consensus targets $18.00 representing 14% upside potential.
Outlook remains positive with projected 2026 revenue of $710M and net income of $62M, though rich valuation requires continued execution. Key risks include competitive pressures and margin sustainability. With 60% analyst buy ratings and improving cash flow projections, FIGS offers growth exposure but demands careful risk management given premium multiples.
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
